Cenobamate Drug Development and Commercial rights for Europe Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Cenobamate Drug Development and Commercial rights for Europe General Information

Description

Development and Commercial rights of a drug for Europe based in Switzerland.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Zählerweg 6
  • 6300 Zug
  • Switzerland
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Corporate Office
  • Zählerweg 6
  • 6300 Zug
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cenobamate Drug Development and Commercial rights for Europe Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cenobamate Drug Development and Commercial rights for Europe‘s full profile, request access.

Request a free trial

Cenobamate Drug Development and Commercial rights for Europe Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cenobamate Drug Development and Commercial rights for Europe‘s full profile, request access.

Request a free trial

Cenobamate Drug Development and Commercial rights for Europe FAQs

  • Where is Cenobamate Drug Development and Commercial rights for Europe headquartered?

    Cenobamate Drug Development and Commercial rights for Europe is headquartered in Zug, Switzerland.

  • What industry is Cenobamate Drug Development and Commercial rights for Europe in?

    Cenobamate Drug Development and Commercial rights for Europe’s primary industry is Buildings and Property.

  • Is Cenobamate Drug Development and Commercial rights for Europe a private or public company?

    Cenobamate Drug Development and Commercial rights for Europe is a Private company.

  • What is the current valuation of Cenobamate Drug Development and Commercial rights for Europe?

    The current valuation of Cenobamate Drug Development and Commercial rights for Europe is .

  • What is Cenobamate Drug Development and Commercial rights for Europe’s current revenue?

    The current revenue for Cenobamate Drug Development and Commercial rights for Europe is .

  • Who are Cenobamate Drug Development and Commercial rights for Europe’s investors?

    SK Biopharmaceuticals has invested in Cenobamate Drug Development and Commercial rights for Europe.

  • When was Cenobamate Drug Development and Commercial rights for Europe acquired?

    Cenobamate Drug Development and Commercial rights for Europe was acquired on 20-Feb-2019.

  • Who acquired Cenobamate Drug Development and Commercial rights for Europe?

    Cenobamate Drug Development and Commercial rights for Europe was acquired by Arvelle Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process